COVID hypetrain brought in a ton of money that the company could not otherwise have raised. Remember our share price was $0.06 with like $700K cash and $7M in liabilities in early 2020. We raised money during COVID 5-10x more efficiently than if we tried to do it with just B-OM - truthfully we wouldn't have been able to raise $10M...pre-COVID IPIX essentially failed.
Now we have some cash padding. Not enough to run a trial but several years worth of salaries at least.
Also, COVID screwed with many clinical trials even if we had the money.
2019 was devoted to B for a variety of inflammatory bowel diseases, including rectum and "the pill" for oral use. It was reported at a shareholder meeting that a B-OM deal was nixed when there was a change of CEO at an interested pharma. Leo may have thought other offers would be coming. Then Covid hit in early 2020 and the focus shifted to anti-viral and anti-inflammatory aspects of B. But it didn't hit primary endpoints in Nov. 2021, so another pivot back to B-OM and hire a business development director to "get it done." My speculation is that Leo has always had high numbers in mind for B indications, given the addressable markets, and shunned low ball discussions. Perhaps there was push back from pharmas interested in B-OM, so Leo had the payer analysis done. If anyone is interested, they now have current information about the addressable market and lack of viable candidates. I hope the next PR is a term sheet.